Parametric Portfolio Associates LLC Has $1.53 Million Holdings in Glaukos Corporation (GKOS)

Parametric Portfolio Associates LLC cut its stake in Glaukos Corporation (NYSE:GKOS) by 40.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,926 shares of the medical instruments supplier’s stock after selling 24,635 shares during the period. Parametric Portfolio Associates LLC owned 0.11% of Glaukos Corporation worth $1,531,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. California Public Employees Retirement System grew its stake in shares of Glaukos Corporation by 10.5% in the second quarter. California Public Employees Retirement System now owns 8,400 shares of the medical instruments supplier’s stock worth $348,000 after purchasing an additional 800 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Glaukos Corporation by 1.4% in the second quarter. PNC Financial Services Group Inc. now owns 70,313 shares of the medical instruments supplier’s stock worth $2,915,000 after purchasing an additional 994 shares in the last quarter. GSA Capital Partners LLP grew its stake in shares of Glaukos Corporation by 3.7% in the second quarter. GSA Capital Partners LLP now owns 35,080 shares of the medical instruments supplier’s stock worth $1,455,000 after purchasing an additional 1,237 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Glaukos Corporation by 6.2% in the first quarter. Teachers Advisors LLC now owns 29,512 shares of the medical instruments supplier’s stock worth $1,514,000 after purchasing an additional 1,723 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its stake in shares of Glaukos Corporation by 740.6% in the second quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock worth $147,000 after purchasing an additional 3,118 shares in the last quarter.

In related news, CEO Thomas William Burns sold 73,788 shares of the firm’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $41.36, for a total transaction of $3,051,871.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Orbimed Advisors Llc sold 325,000 shares of the firm’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $37.93, for a total value of $12,327,250.00. The disclosure for this sale can be found here. Insiders have sold 980,200 shares of company stock valued at $37,900,263 in the last ninety days. Company insiders own 16.40% of the company’s stock.

Several research analysts have recently issued reports on the company. BidaskClub raised Glaukos Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, September 12th. Cantor Fitzgerald reissued a “buy” rating and issued a $60.00 price target (up previously from $54.00) on shares of Glaukos Corporation in a research note on Thursday, September 14th. Zacks Investment Research cut Glaukos Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Roth Capital decreased their price target on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating for the company in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $56.00 price target on shares of Glaukos Corporation in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $47.86.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/11/13/parametric-portfolio-associates-llc-has-1-53-million-holdings-in-glaukos-corporation-gkos.html.

Glaukos Corporation (NYSE GKOS) opened at $30.09 on Monday. Glaukos Corporation has a 52 week low of $28.72 and a 52 week high of $52.49. The firm has a market capitalization of $1,040.07, a PE ratio of 250.75 and a beta of 1.25.

Glaukos Corporation (NYSE:GKOS) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.06. Glaukos Corporation had a positive return on equity of 3.50% and a negative net margin of 0.64%. The business had revenue of $40.41 million during the quarter, compared to analysts’ expectations of $38.69 million. During the same quarter last year, the business posted $0.03 earnings per share. The company’s quarterly revenue was up 36.6% on a year-over-year basis. sell-side analysts predict that Glaukos Corporation will post -0.02 earnings per share for the current fiscal year.

Glaukos Corporation Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply